{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:45:32Z","timestamp":1792003532606,"version":"4.4.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","semarthritisrheumatism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.semarthrit.2015.05.003","type":"journal-article","created":{"date-parts":[[2015,6,15]],"date-time":"2015-06-15T19:23:17Z","timestamp":1434396197000},"page":"156-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["Risk of liver injury among methotrexate users: A meta-analysis of randomised controlled trials"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2538-3362","authenticated-orcid":false,"given":"Richard","family":"Conway","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candice","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Coughlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2015.05.003_bib1","unstructured":"Sweetman S. (editor), Martindale: The complete drug reference. London: Pharmaceutical Press. \u3008https:\/\/www.medicinescomplete.com\/mc\/martindale\/current\/search.htm?q=methotrexate&searchButton=+\u3009, 2005 [Accessed 13.09.14]."},{"key":"10.1016\/j.semarthrit.2015.05.003_bib2","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","article-title":"American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis","volume":"59","author":"Saag","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib3","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1517\/17425247.2012.642362","article-title":"Methotrexate: a detailed review on drug delivery and clinical aspects","volume":"9","author":"Khan","year":"2012","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib5","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/ard.2008.094474","volume":"68","author":"Visser","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib6","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0889-857X(05)70365-3","article-title":"Methotrexate hepatotoxicity","volume":"23","author":"West","year":"1997","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib7","unstructured":"Livertox\u00ae. Accessed [13.09.14]. \u3008http:\/\/livertox.nih.gov\/Methotrexate.htm\u3009"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib8","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/rheumatology\/kep176","article-title":"Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate","volume":"48","author":"Amital","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/00044011-200626020-00001","article-title":"Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis","volume":"26","author":"Tilling","year":"2006","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib10","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/ard.2008.093690","article-title":"Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib11","doi-asserted-by":"crossref","first-page":"7327","DOI":"10.3748\/wjg.v19.i42.7327","article-title":"Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver","volume":"19","author":"Rojas-Feria","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib12","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/art.38322","article-title":"Methotrexate and lung disease in rheumatoid arthritis\u2014a meta-analysis of randomized controlled trials","volume":"66","author":"Conway","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib13","unstructured":"The Cochrane Collaboration, Review Manager (RevMan) [Computer program]. Version 5.1. Copenhagen: The Nordic Cochrane Centre; 2011."},{"key":"10.1016\/j.semarthrit.2015.05.003_bib14","unstructured":"Higgins JPT, Green S. (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. [Internet. Accessed 01.04.14.] Available from \u3008www.cochrane-handbook.org\u3009."},{"key":"10.1016\/j.semarthrit.2015.05.003_bib15","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1136\/annrheumdis-2013-204761","article-title":"Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study","volume":"73","author":"Dougados","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib16","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1053\/j.gastro.2013.11.024","article-title":"Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn\u05f3s disease","volume":"146","author":"Feagan","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib17","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3109\/s10165-012-0742-6","article-title":"A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis","volume":"23","author":"Takeuchi","year":"2013","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1142\/S0192415X13500195","article-title":"The new use of an ancient remedy: a double-blinded randomized study on the treatment of rheumatoid arthritis","volume":"41","author":"Chen","year":"2013","journal-title":"Am J Chin Med"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10067-012-2096-z","volume":"32","author":"Chen","year":"2013","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib20","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2133.2012.11015.x","article-title":"A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis","volume":"167","author":"Gottlieb","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib21","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","article-title":"A randomized placebo-controlled trial of methotrexate in psoriatic arthritis","volume":"51","author":"Kingsley","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib22","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJMoa1010858","article-title":"A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis","volume":"365","author":"Reich","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib23","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/s10165-010-0405-4","article-title":"Leflunomide or methotrexate? Comparison of clinical efficacy and safety in low socio-economic rheumatoid arthritis patients","volume":"21","author":"Ishaq","year":"2011","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib24","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1136\/ard.2009.116319","article-title":"Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study","volume":"69","author":"Keystone","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2008.105197","article-title":"Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study","volume":"69","author":"Jones","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib26","doi-asserted-by":"crossref","first-page":"R180","DOI":"10.1186\/ar2870","article-title":"A multicenter, double-blind, randomized, controlled phase III clinical trial of chicken type II collagen in rheumatoid arthritis","volume":"11","author":"Wei","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib27","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/art.24638","volume":"60","author":"Emery","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib28","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/art.24643","article-title":"Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate","volume":"61","author":"Lu","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib29","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/s10165-008-0125-1","volume":"19","author":"Nishimoto","year":"2009","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib30","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00296-008-0681-x","article-title":"A comparison study of a recombinant tumor necrosis factor receptor:Fc fusion protein (rhTNFR:Fc) and methotrexate in treatment of patients with active rheumatoid arthritis in China","volume":"29","author":"Hu","year":"2009","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib31","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/art.23824","article-title":"A randomized, double-blind, multicenter, controlled clinical trial of chicken type II collagen in patients with rheumatoid arthritis","volume":"59","author":"Zhang","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib33","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib34","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1136\/ard.62.4.291","article-title":"Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial","volume":"62","author":"Gerards","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib35","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/1529-0131(200109)44:9<1984::AID-ART346>3.0.CO;2-B","article-title":"Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group","volume":"44","author":"Cohen","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib36","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","article-title":"A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis","volume":"343","author":"Bathon","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib37","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/rheumatology\/39.6.655","article-title":"A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis","volume":"39","author":"Emery","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib38","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/rheumatology\/39.3.316","article-title":"A clinical study of CPH 82 vs methotrexate in early rheumatoid arthritis","volume":"39","author":"Lerndal","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib39","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/ard.58.4.220","article-title":"Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components","volume":"58","author":"Dougados","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib40","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/rheumatology\/36.10.1082","article-title":"Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial","volume":"36","author":"Haagsma","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib41","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(97)01300-7","article-title":"Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis","volume":"350","author":"Boers","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib42","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/rheumatology\/36.3.345","article-title":"Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a double-blind parallel study of 174 patients","volume":"36","author":"Rau","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib43","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM199605163342002","article-title":"Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications","volume":"334","author":"O\u05f3Dell","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib44","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/art.1780350802","article-title":"Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial","volume":"35","author":"Willkens","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib45","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/art.1780350304","article-title":"Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial","volume":"35","author":"Williams","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib46","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/art.1780330305","article-title":"Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. A thirty-six-week, double-blind trial","volume":"33","author":"Weinblatt","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib47","first-page":"1017","article-title":"Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature","volume":"27","author":"Visser","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib48","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/ard.2008.101378","article-title":"Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and\/or leflunomide","volume":"69","author":"Curtis","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib49","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10067-012-2136-8","article-title":"Risk of alanine transferase (ALT) elevation in patients with rheumatoid arthritis treated with methotrexate in a DAS-steered strategy","volume":"32","author":"Dirven","year":"2013","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib50","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/art.1780360307","article-title":"Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis","volume":"36","author":"Walker","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib51","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1186\/ar3085","article-title":"Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes","volume":"12","author":"Quintin","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib52","first-page":"342","article-title":"The histologic effects of low-dose methotrexate therapy for primary biliary cirrhosis","volume":"122","author":"Bach","year":"1998","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib53","doi-asserted-by":"crossref","first-page":"682","DOI":"10.7326\/0003-4819-126-9-199705010-00002","article-title":"Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment","volume":"126","author":"Kaplan","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib54","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1007\/s10620-010-1291-5","article-title":"Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid","volume":"55","author":"Kaplan","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib55","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1136\/ard.2009.112136","article-title":"Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis","volume":"69","author":"Sokolove","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib56","doi-asserted-by":"crossref","first-page":"17352","DOI":"10.3748\/wjg.v20.i46.17352","article-title":"Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management","volume":"20","author":"Rossi","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.semarthrit.2015.05.003_bib57","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/ard.2008.099861","article-title":"Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis","volume":"68","author":"Katchamart","year":"2009","journal-title":"Ann Rheum Dis"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017215001092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017215001092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T15:51:50Z","timestamp":1537545110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017215001092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0049017215001092"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2015.05.003","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of liver injury among methotrexate users: A meta-analysis of randomised controlled trials","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2015.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}